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Valve replacement has been one of the most important
advances in the management of patients with valvular
heart disease. The 10 and 15 year survival rate after
isolated aortic and mitral valve replacement with the
Starr-Edwards valve is 56 and 44%, respectively. At 5
and 7 years, survival with the Bjork-Shiley, porcine bio-
prosthesis and the Starr-Edwards valve is similar. Pa-
tients operated on during the last 5 to 10 years have a
much better survival rate than those operated on in the
1960s; therefore, the 10 and 15 year survival of those
operated on recently should improve.
All patients with a mechanical prosthesis need long-
Many exciting events have occurred in the last 25 years in
the field of valvular heart disease; one of the most important
has been the emergence of surgery as the dominant force
in the management of patients with severe lesions. The first
diseased aortic and mitral valves were replaced with ball-
valve prostheses in 1960 by Harken and Starr and their
colleagues. The first homografts were utilized a few years
later for aortic valve replacement by Ross and Barratt-Boyes.
Since then, many valve replacement devices have been eval-
uated; most have not stood the test of time. If valve re-
placement is successful and uncomplicated, most patients
experience an improvement in symptomatic state. and there-
fore, in the quality of life (1-14). After mitral valve surgery,
pulmonary hypertension is relieved, (15-17); and after aor-
tic valve replacement, the compensatory mechanisms of left
ventricular hypertrophy or dilation, or both, regress and
impaired ventricular function improves (9,13,18-20). The
role of valve replacement in controlling infection and heart
failure in infective endocarditis is established (21.22); there-
fore, its role in prolonging life seems reasonable. This prob-
ably also applies to patients with severe aortic stenosis,
particularly those with heart failure (9,19). For all of these
reasons, valve replacement has been recognized as the most
important advance since 1960 for the management of pa-
tients with valvular heart disease. Valve replacement has
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term anticoagulant therapy with drugs of the coumadin
type. Porcine bioprostheses have a low failure rate up
to 5 years after valve replacement; after this, valve fail-
ure occurs at an increasing rate, but the incidence at 10
and 15 years is not known. Valve replacement usually
produces a marked improvement in the symptomatic
status of the patient because of improved hemodynamics;
ventricular function is improved in selected subsets of
patients. The role of long-term vasodilator therapy has
not been fully determined. Antibiotic prophylaxis for
secondary prevention of rheumatic carditis and for pre-
vention of infective endocarditis is important.
saved many lives. has enabled a larger number of patients
to lead a more active and useful life, and has reached a
stage when most patients with valvular heart disease can
now be considered potential candidates for surgery. Before
we review the results of valve replacement in greater detail,
it is useful to briefly consider some problems with data
analysis.
Problems With Data Analysis
1. Within the last 10 years presentation of time-related
events has been correctly performed almost uniformly
by use ofactuarial techniques. However, it is important
to remember that mean survival rates by themselves do
not provide adequate information (7) because the pre-
cision of the estimated mean is directly affected by the
sample size used to determine the mean. The measure
of this precision is provided by the standard error of
the mean. In general, the use of ± 1 or 2 standard errors
of the mean provides an approximate 70 or 95% con-
fidence interval for the true mean; that is, 70 or 95%
of the time the true mean will lie within the estimated
1 or 2 standard errors.
2. Comparison of survival data after valve replacement
with survival data from the "normal" United States
population is of very limited value (23) and at times
may give misleading impressions. The population of
the United States contains not only normal persons but
also persons with malignant tumors, renal and pul-
monary failure, operable and inoperable coronary artery
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disease, emotional disorders and other conditions that
put them at high risk of death. The patients chosen for
valve replacement are usually highly selected, because
they do not have other diseases that are likely to shorten
their life. Moreover, patients with valvular heart disease
who are not operated on and those who have undergone
valve replacement are also included in the overall "nor-
mal" population of the United States.
3. When results of any particular procedure are evalu-
ated, the numbers of patients who were excluded from
the evaluation should be carefully scrutinized. Mortality
and other statistics are influenced by patients who were
excluded from the analysis.
4. Preoperative information on patients undergoing valve
replacement should be carefully examined. If patients
are operated on without undergoing complete preop-
erative hemodynamic and angiographic studies, then it
is possible or even likely that some of them do not have
severe valve disease (7,24).
5. Survival curves that exclude hospital mortality may be
of value in comparing long-term results of various de-
vices. However. it is essential to include the hospital
mortality statistics to obtain a realistic idea of overall
survival.
6. Comparison of data from different studies can be mis-
leading. Accurate comparison of the results of two stud-
ies, whether they are from the same center or from
different centers, requires that the patient populations
at the start of the studies be identical. Such a situation
is unlikely to be obtained except by prospective, well
designed, well conducted studios.
7. Accurate evaluation of prosthesis failure can be diffi-
cult. It cannot be based solely on the number of patients
who have been reoperated on, because patients may
have prosthesis failure and not come to surgery. Unless
almost all patients are examined by the investigators,
the diagnosis of prosthesis failure on the basis of the
appearance of a "new" murmur may be unreliable.
Patients with prosthesis failure may be asymptomatic,
and detection of mechanical prosthesis failure by non-
invasive methods is not reliable.
8. It has been learned painfully over the years that one
should be careful about extrapolating data from one
device to another, or from one model of a device to
another model of the same device. Even subtle changes
in design intended to reduce complications may produce
new unexpected problems.
9. Similarly, the evaluation of complications of a pros-
thesis can be difficult. For example, when patients de-
scribe certain symptoms. a judgment has to be made
as to whether or not these symptoms resulted from
systemic emboli. In addition. not all symptoms and
bleeding complications are necessarily reported to the
physician. Thus. I offer the hypothesis that when we
are reviewing data on complications. we are examining
the least incidence of complications.
10. Valvular surgery has evolved and changed over the last
22 years (1,2). The results obtained with valve replace-
ment in the last 10 years are generally superior to those
obtained in the first 12 years. Reasons for this include
improved operative techniques and valve replacement
devices and better management of patients in the per-
ioperative period and better management of patients
with prosthetic valves. Perhaps the most important fac-
tor is that patients are being operated on earlier in the
course of their valve disease. In the 1960s mainly pa-
tients in functional classes III and IV had valve re-
placement; now patients have valve replacement when
they are in functional class I, II or III and the percent
of patients undergoing valve replacement who are in
functional class IV is greatly reduced.
Valve Replacement
Operative Mortality
Operative mortality is 5% or greater for single and 10% or
greater for double valve replacement (1-14,22,25-29). Fac-
tors that contribute to operative mortality are heart failure,
impaired left ventricular function, functional classes III and
IV and associated coronary artery disease. A major cause
of operative mortality is the occurrence of perioperative
myocardial damage (Table 1). Better techniques of myo-
cardial protection have resulted in a lesser incidence of
myocardial damage and. thus, a reduction in operative mor-
tality (10).
Perioperative Myocardial Damage
The use of cold cardioplegia with potassium ion arrest and
other techniques for better myocardial protection during open
heart surgery have led to a significant reduction in periop-
erative myocardial damage (Table 1) (10), the incidence of
which is 5% or greater. These improvements have resulted
in a lowering of the operative mortality rate; the long-term
benefits of adequate myocardial protection should become
apparent in the next decade.
Functional Improvement
After successful valve replacement. most patients experi-
ence an improvement in functional status because of relief
of symptoms (1-14.22.25).
Late Survival
A 20 year follow-up study is available on patients operated
on from 1960 to 1980 by Albert Starr (2). The long-term
survival rates after isolated aortic and mitral valve replace-
ment were similar; the survival rate at 10 and 15 years was
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Table 1. Incidence of Perioperative Myocardial Infarction (M\) Before and After Use of Cold Cardioplegia for
Myocardial Protection*
Patients With
Op. Deaths
MI in
Assoc. CAD Op. Survivors
Cold Patients Total
Cardioplegia (total no.) no. (%) Total Due to MI no. (%) MI
No 128 31 (24) 18 II II (10) 17o/c
Yes 113 36 (32) 3 0 2 (1.8) 1.8%
*Data are based on two series of consecutive patient; undergoing aortic valve replacement in the early and late 1970,. Before use of cold cardioplegia. 61c/c II I of 18)
of operative deaths were associated with perioperative myocardial damage.
Assoc. = associated; CAD = coronary artery disease; Op. = operative.
56 and 44%, respectively (Fig. I). For double valve re-
placement the survival rate at 10 and 15 years was 45 and
27%, respectively; and for triple valve replacement the sur-
vival rate was 37 and 23%, respectively. The lower survival
rate of patients undergoing double and triple valve replace-
ment was the result of increased operative and late mortality.
Multivariate analysis showed that the year of operation was
the most important determinant of late survival. For isolated
valve replacement, there was a significant (p < 0.0 I) in-
crease in survival at 5 years in the current time frame (from
67 to 73%), primarily because of a decrease in operative
mortality (Fig. 2). In the current time frame, the 5 year
survival rate of patients undergoing aortic or mitral valve
replacement was 71 and 78%, respectively.
The causes ofdeath are shown in Figure 3. The cardiac-
related causes of death were heart failure, myocardial in-
farction, arrhythmia and sudden deaths. The causes of sud-
den death are listed in Table 2. The prosthesis-related causes
of late death were thromboembolism, ball variance, endo-
carditis and hemorrhage. The 5 year survival data with the
Bjork-Shiley prosthesis (Fig. 4) (3,25) and the porcine het-
erograft (Fig. 5) (4-6) and the 10 year survival with the
Bjork-Shiley aortic prosthesis (3) are similar to survival data
obtained with the Starr-Edwards valve.
Aortic stenosis with clinical heart failure. The 7 year
survival rate of this subgroup of patients is 67 ± II % (mean
± standard error of the mean); that of operative survivors
is 84 ± 10% (1,9). Because the impaired left ventricular
function that is present preoperatively improves markedly
after valve replacement, provided there has been no peri-
operative myocardial damage, variables of left ventricular
systolic pump function are not good predictors of late sur-
vival in this subset of patients (14).
Aortic stenosis in patients aged 60 years or more. The
10 and 12 year survival rate of these patients is 56 ± 9%
(Fig. 6) and that of operative survivors excluding those who
died of noncardiac causes is 68±9% (1,14); one-third of
the late deaths were not of cardiac origin or related to the
prosthesis or anticoagulant therapy.
Aortic regurgitation (Table 3). The 5 year survival of
these patients is best predicted by variables of left ventricular
systolic pump function (30). The 5 year survival rate of
patients with a preoperative left ventricular ejection fraction
of 0.45 or greater was 87% versus 54% in patients with an
ejection fraction of less than 0.45 (p<0.04)(30); the rate
was 92% in patients with a cardiac index of 2.5 liters per
nr' or greater versus 66% in those with an index of less
than 2.5 (p<0.04) (11,30). Clinically valuable information
is obtained from left ventricular ejection fraction and func-
tional class of the patient: patients who had an ejection
fraction of 0.50 or greater and were in functional class II
to IV or who had an ejection fraction of less than 0.50 but
were in functional class I or II had a 5 year survival rate of
90 to 100%; only patients with an ejection fraction of less
100
Figure 1. Actuarial survival curve for all patients undergoing
initial single aortic and single mitral valve replacement and
those undergoing double and triple valve replacement with a
Starr-Edwards caged-ball valve prosthesis from September
1960 through September 1980. N = number of patients.
(Reprinted from Teply J. Grunkemeier G. Sutherland HD. et
a!' [2]. with permission.)
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Figure 2. Survival according 10 time of implantation for single
initial aortic and mitral valve replacement with a Starr-Edwards
caged-ball valve prosthesis . p = probability.
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than 0.50 who were in functional class III or IV had a lower
5 year survival rate (63%) (4,30) .
Mitral valve disease. Patients with predominant mitral
regurgitation had a significantly (p<0.05) lower 5 year sur-
vival rate (54%) than that of patients with mitral stenosis
or mixed mitral lesions, whose survival rate was 68 and
71%, respectively (27). In patients with mitral regurgitation,
5 year survival after valve replacement is also determined
by the etiology of the mitral regurgitation and by the func-
tional class of the patient. The 5 year survival rate of patients
with mitral regurgitation secondary to rheumatic , connective
tissue or ischemic heart disease was 57 , 54 and 32%, re-
spectively (Fig . 7); the 8 year survival rate of patients in
functional classes I, II and III plus IV, was 64,52 and 40%,
respectively (27) .
Late Complications
The major complications that occur after valve replacement
are listed in Table 4 (28,29).
Endocarditis. Prosthetic endocarditis occurs with all types
of valve replacement devices at a rate of I% per year or
less; patients are at risk for prosthetic endocarditis for life.
Early prosthetic endocarditis , occurring within 2 months of
valve replacement, is usually associated with staphylococcal
and gram-negative bacillary infection, and has an 80 to
100% mortality rate if not treated with a second valve re-
placement in addition to antibiotic therapy (31) . Late pros-
thetic endocarditis is associated with organisms that are
similar to those seen with native valve endocarditis. Ap-
proximately 50% of these patients respond to medical treat-
ment alone; the remainder also require a second valve
replacement.
Prosthetic dysfunction. Structural failure of commonly
used mechanical prosthe ses is not frequent ; when it occurs.
it usually involves the strut s of the prosthe sis. Strut fracture
usually does not lead to cata strophic complications; when
it is recognized , the patients are able to undergo a second
valve replacement. Structural failure is a more common
problem with bioprostheses, which undergo degeneration,
perforation and calcification , with resulting prosthetic ste-
nosis or regurgitation, or both (Table 5). Porcine bioprosthetic
failure occurs at a low rate up to 5 years after valve re-
placement, thereafter occurring at an increasing rate (4,5)
(Fig . 8). The incidence at 10 years is unknown, but data
currently available suggest that it may be as low as 15%
or as high as 30 to 40%. Bioprosthetic valve failure cannot
be accurately detected by history, physical examination or
noninvasive techniques (32).
1960-72 1973-80
Cardiac 52% .....--~~
Figure 3. Causes of late death after single aortic and mitral
valve replacement with a caged-ball valve prosthesis. In both
time periods the major cause of late death is of cardiac origin.
The proportion of deaths due to prosthesis-related causes is
smaller in the later time period. but more deaths were due to
unknown causes in the second time frame. pt.-yr. = patient-
year. (Reprinted from Teply J, Grunkemeier G, Sutherland
HD, et al. [2], with permission.)
Total: 100°,4 =5.1%/pt.-yr. Total: 100%=4.5%/pt.-yr.
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Table 2. Causes of Sudden Death After Valve Replacement
1. Tachyarrhythmias
Primary
Secondary
I) LV dysfunction
a) Preoperative: same or worse postoperatively
b) Perioperative myocardial damage
c) Late postoperative
i) Unrecognized perioperative myocardial damage
ii) Prosthetic valve dysfunction
iii) Other complications of prosthetic valves
iv) Associated disease-valvular, infectious, coro-
nary artery and myocardial
2) Other disorders
a) Electrolyte disturbances
b) Drug toxicity and adverse effects
c) Other diseases
II. Bradyarrhythmias
Primary
Secondary
I) Perioperative damage
2) Other disorders
a) Electrolyte disturbances
b) Drug toxicity and adverse effects
c) Other diseases
III. Prosthetic Valve Dysfunction
Obstruction
I) Thrombus
2) Calcification and degeneration
Regurgitation
I) Degeneration
2) Structural failure
3) Dehiscence
Valve prosthesis-patient mismatch
IV. Coronary Artery Disease
Atherosclerosis
Perioperative coronary artery damage
Embolic
V. Other Cardiac and Noncardiac Disorders
The incidence of' 'sudden" prosthetic thrombosis is low
except with the Bjork-Shiley valve. The data of Bjork and
Henze from Sweden (3) show that the incidence of throm-
bosed aortic, mitral and tricuspid valve prostheses was 0.3,
1.3 and 2.3 per 100 patient-years, respectively. At 4 years
the incidence rate of thrombosed aortic and mitral Bjork-
Shiley prostheses at the University of Alabama (25) was 3
and 13%, respectively (Table 6). The incidence of throm-
bosed mitral prostheses in both studies was four times greater
than that of thrombosed aortic prostheses. The incidence of
thrombosed aortic and mitral prostheses was much higher
in the data from the University of Alabama than in that from
Sweden. The reason for this difference is not known but
may relate to the different patient populations, the inclusion
in the Swedish series of only patients with a "perfect degree
of anticoagulation" or other factors. Bjork and Henze (3)
noted a 27-fold increase in the incidence of thrombosed
aortic prostheses if anticoagulation was "discontinued or
omitted. " The University of Alabama data showed a very
high mortality rate (87%) of patients with a thrombosed
Bjork-Shiley prosthesis. Perhaps the data from the Uni-
versity of Alabama are more relevant for the usual clinical
situation in the United States.
Thromboembolism. Thromboembolism is a major prob-
lem associated with use of prosthetic heart valves; the
incidence rate is 1 to 2% per year with aortic valve replace-
ment and 2 to 5% per year with mitral valve replacement.
The incidence of thromboembolism with mechanical pros-
thetic valves and porcine bioprostheses has been similar;
patients with mechanical valves had received anticoagulant
therapy, however. a very small percent of patients with an
aortic bioprosthesis received anticoagulant therapy and a
significant percent of patients with a mitral bioprosthesis
had received anticoagulant therapy. Anticoagulant therapy
with drugs of the warfarin type must be used in all patients
with a mechanical prosthesis unless there is a specific con-
traindication to the use of these drugs: anticoagulant therapy
must also be used in patients with a porcine heterograft who
have a supraventricular arrhythmia such as atrial fibrillation
or a very large left atrium.
Hemorrhage. Anticoagulant therapy causes bleeding
episodes: major episodes occur in about 1 to 2% of patients
per year, death occurs in ::;0.5% of patients per year and
minor bleeding episodes occur in about 4 to 8% of patients
per year. It is probable that the incidence of bleeding is less
in patients in whom adequate anticoagulant therapy can be
easily maintained.
Valve prosthesis-patient mismatch. This condition
(33,34) is present when the effective area of the prosthetic
valve, after valve insertion into the patient, is less than that
of the normal human valve. The reduction in prosthetic valve
area is usually mild to moderate in severity and often of no
immediate clinical significance. Occasionally, the patient
will be hemodynamically and symptomatically worse after
valve replacement (33,34). The mismatch results mainly
from two factors. First, the in vitro effective prosthetic valve
area of almost all types of valve replacement devices that
can be inserted in patients is less than that of the normal
human valve. The in vivo effective prosthetic valve area is
even further reduced because of tissue ingrowth and en-
dothelialization; therefore, these devices can be considered
"stenotic." Second, the problem is compounded in some
patients because the size of the prosthesis that can be inserted
is limited by the size of the anulus, which is small compared
with the size of the patient, and by the size of the cavity in
which the prosthesis must lie. Two issues need emphasis:
1) Valve prosthesis-patient mismatch occurs with all valve
replacement devices, and 2) the effective orifice size is only
one factor that has to be taken into account when selecting
a valve replacement device for an individual patient.
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Figure 4. Actuarial survival rate after valve replace-
ment with the Bjork-Shiley prosthesis. The number of
patients at risk at the beginning of each year of ob-
servation is indicated. AYR = aortic valve replacement:
MYR = mitral valve replacement: POST-OP = post-
operative. The operative mortality is not included in
the late survival. Also. follow-up data on an adequate
number of patients are available for up to 9 years on
patients with aortic valve replacement. for only 6 years
on patients with mitral valve replacement and for less
Then 5 years on those with double valve replacement.
(Reprinted from Bjork YO. Henze A [3], with permission.)
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Reoperation. This is a serious and a life-threatening
complication. It is usually undertaken for prosthetic dys-
function, endocarditis or dehiscence. Occasionally it is un-
dertaken because of repeated thromboemboli and hemor-
rhage associated with anticoagulant therapy and because of
valve prosthesis-patient mismatch.
Choice of Prosthesis
Currently in the United States, two main types of prosthetic
heart valves are being implanted-mechanical prostheses
and bioprostheses. The two main types of mechanical valves
being used are a ball and cage valve (Starr-Edwards valve)
and a tilting disc valve (Bjork-Shiley valve). The bio-
prostheses are porcine heterografts (Hancock and Carpen-
tier-Edwards). After the initial valve replacements in 1960,
Starr improved the ball and cage valve, aggressively fol-
lowed up patients and made a detailed evaluation of the
results with sophisticated statistical methods, including use
of confidence level. Starr's pioneering work has established
the standards by which other prosthetic heart valves are
judged: "As is the case for prosthetic mitral valves, the
Starr-Edwards caged-ball valve is the 'bench mark' in aortic
Figure 5. Actuarial survival rate of 128 patients with
isolated aortic and mitral valve replacement with a porcine
heterograft. A small number of patients have been fol-
lowed up after 6 years. Also. the listed numbers include
patients with aortic and with mitral valve replacement.
(Reprinted from Cohn LH, Mudge GH. Pratter F. Collins
JJ Jr. [6]. with permission.)
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Figure 6. Actuarially determined survival of 99 con-
secutive patients aged 60 years or older after aortic
valve replacement for calcific aortic stenosis. The
dashed line is the actuarially determined survival with
the noncardiac deaths excluded. (Reprinted from Mur-
phy ES, Lawson RM, Starr A, Rahimtoola SH [14],
by permission by the American HeaI1 Association.
Inc.)
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valve replacement" (35). The survival of patients with the
Silastic ball Starr-Edwards valve, which has been in clinical
use since 1966, is shown in Figure 9.
Mechanical prosthesis versus porcine hetero-
graft. The main advantages of the mechanical prostheses
are their proved durability (Starr-Edwards valves up to 15
to 20 years [2], the Bjork-Shiley valves up to 8 to 10 years
in the aortic position and 5 to 7 years in the mitral position
[3,25]) and the known complications with their rate of oc-
currence. The greatest advantage of the porcine heterografts
is that anticoagulant therapy is not required for patients with
sinus rhythm. Because the mechanical valve with antico-
agulation and the heterograft valve without anticoagulation
have demonstrated similar rates of thromboembolism, the
main disadvantage of mechanical valves is the need for
anticoagulation and its associated morbidity and mortality.
The greatest disadvantage of heterografts is their unknown
durability after 10 years.
The choice of a prosthetic heart valve should be made
after careful consideration of all factors. Porcine bio-
prostheses are indicated for patients who cannot take an-
ticoagulant agents, women of child-bearing age who desire
pregnancy and patients whose life expectancy from other
diseases is likely to be less than 7 years after valve replace-
ment. Mechanical prostheses are indicated for all patients
Table 3. Aortic Valve Replacement for Aortic Regurgitation
NYHA
Functional 5 Year Survival
LVEF Class Rate* (o/c)
~ 0.50 II 100
III, IV 90 ± lOt
< 0.50 I, II 88 ± 11
III. IV 63 ± 17
*Includes operative mortality. t Excludes 3 late noncardiac deaths.
LVEF = left ventricular ejection fraction: NYHA = New York Heart Association.
with atrial fibrillation and for patients who require valves
in the smaller sizes, patients with "long" life expectancy,
and patients who want to reduce the chance of reoperation
to a minimum.
Some investigators recommend that bioprostheses be used
in all patients aged 60 years and older at the time of valve
replacement. Our own data in patients aged 60 years or
older with critical aortic stenosis indicate that 50% or more
of these patients will be alive 12 years after valve replace-
ment (14). Because the average age at the time of valve
replacement was 68 years, the prospect of reoperating for
bioprosthetic failure on 15 to 30% of these survivors 10
years after initial valve replacement at an average age of
78 years does not appear to be very attractive. Thus, the
automatic choice of a porcine bioprosthesis for patients aged
60 years and older cannot be justified at present.
Problems with the Bjork-Shiley valve. The previously
described 7 year survival in the mitral position and 10 year
survival in the aortic position with the Bjork-Shiley valve
is derived from an earlier model of this prosthesis. The new
model of the Bjork-Shiley valve, the convexo-concave valve,
which is the only one currently available in the United States,
has had a short follow-up time and the results at 5 years are
unknown. Already, a problem of strut fracture has emerged
with the new Bjork-Shiley valve. and its magnitude is not
yet fully established. Thus, the known intermediate and
long-term results with use of the new model of the Bjork-
Shiley valve are less than those of the porcine heterograft.
Also, there is the problem of "sudden" prosthetic throm-
bosis which appears to have a "high" incidence rate. par-
ticularly with valves in the mitral position (3,25).
Newer devices. If new prostheses or prostheses with
modifications are planned to be used. they must now con-
form to the law on cardiovascular devices that is regulated
by the Federal Food and Dru~ Administration (36). Because
we have a choice of several valves with a proved record
from 7 to 20 years, the routine clinical use of "newer"
devices must be very carefully scrutinized and justified.
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Figure 7. Actuarial survival curves of patients undergo-
ing mitral valve replacement demonstrating the influence
of the etiology of mitral regurgitation on long-term sur-
vival. (Reprintedfrom Salomon NW. Stinson EB. Griepp
RB, Shumway NE [27]. with permission.)
p < 0.05
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Left Ventricular Function
Aortic valve disease and normal preoperative ven-
tricular function (19). In patients with aortic stenosis whose
left ventricular ejection fraction was normal preoperatively,
the ejection fraction remained normal postoperatively (0.71
versus 0.76) provided that there was no significant periop-
erative myocardiai damage. However, a significant reduc-
tion in left ventricular hypertrophy occurred (left ventricular
mass was reduced from 229 ± 39 to 133 ± 10 g/rrr', p
<0.05), and left ventricular volumes were normal pre- and
postoperatively. In patients with aortic regurgitation, left
ventricular ejection fraction also showed no significant change
(0.64 versus 0.59). Significant reductions in hypertrophy
(mass decreased from 222 ± 18 to 128 ± 17 g/m", p
<0.025) and in left ventricular size (end-diastolic volume
index decreased from 205 ± 22 to 140 ± 24 ml/rrr', p
<0.05) occurred. In both groups, abnormalities of left ven-
tricular end-diastolic pressure and cardiac index, if present
preoperatively, tended to normalize.
Table 4. Major Complications of Valve Replacement
I. Operative mortality
2, Perioperative myocardial infarction
3, Prosthetic endocarditis
4. Prosthetic dehiscence
5. Prosthetic dysfunction
a) Structural failure
b) Thrombosis
c) Hemolysis
6. Prosthetic obstruction usually due to 5a and b, occasionally due to
3.4 and 8
7. Prosthetic regurgitation due to 5a and b. 3 and 4
8. Thromboemboli
9. Hemorrhage with anticoagulant therapy
10. Valve prosthesis-patient mismatch
II. Prosthetic replacement often due to 3. 4 and 5; occasionally due to
8.9 and 10
12. Late mortality. including sudden unexplained death
Aortic stenosis with impaired left ventricular function
and clinical heart failure (9). After successful valve re-
placement, left ventricular end-diastolic pressure normal-
izes (reduced from 22 ± 2.4 to 9 ± L 9 mm Hg). If the
left ventricular end-diastolic volume was increased preop-
eratively, then postoperatively there was a significant re-
duction in end-diastolic volume index from 146 ± 18 to
99 ± 9 ml/rrr' (p <0.025). Left ventricular ejection fraction
increased dramatically from 0.34 ± 0.03 to 0.63 ± 0.05
and mean velocity of circumferential fiber shortening also
increased' from 0.57 ± 0.08 to 1.03 ± 0.18 circumfer-
ences/s (Fig. 10). The change in ejection fraction needs
further mention: 1) Except for the patient who had a peri-
operative myocardial infarction, all patients experienced an
improvement in left ventricular ejection fraction; 2) left
ventricular ejection fraction became normal in two-thirds of
the patients; and 3) the two patients with the lowest ejection
fraction (0.18 and 0.19, respectively) also had dramatic
increases in ejection fraction to 0.56 and 0.57.
In general, these patients have an excellent result from
valve replacement. These results. however, should not nec-
essarily be expected in patients with heart failure associated
with mild (or perhaps moderate) aortic stenosis, because in
these patients heart failure would not be expected to be
related predominantly to the aortic stenosis. Therefore, the
diagnosis of severe aortic stenosis is important. Because the
clinical estimation of the severity of aortic stenosis is often
in error, particularly in the presence of a low cardiac output,
complete hemodynamic evaluation is warranted. For ex-
ample, four of our patients had a mean aortic gradient of
<40 mm Hg (30,30, 33 and 35 mm Hg, respectively) de-
spite the presence of critical aortic stenosis, emphasizing
the need for both measuring cardiac output and calculating
the aortic valve area. In some patients. it may be preferable
to measure these variables both at rest and in a different
hemodynamic state, such as that induced by exercise.
Catheterization-proved severe aortic stenosis with or
without heart failure, treated nonsurgically . is associated
with a 5 year survival rate of 38% and a 10 year survival
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Table 5. A Case of Prosthetic Valve Failure*
Pressures (mm Hg)
Right atrium
Pulmonary artery
Pulmonary artery wedge
Left ventricle
Systemic artery
Heart rate (beats/min)
Cardiac index (liters/min per
rrr ')
Aortic regurgitation
Supravalvular
aortography
Left ventricular angiography
End-diastolic volume
index (ml/rrr')
Ejection fraction
Aortic valve
Peak gradient (mm Hg)
Mean gradient (mm Hg)
Valve area (crrr')
Valve area index (cm2/m2)
April 1978 May 1979 Nov. 1981
Rest Exercise Rest Exercise Rest
(4) (I ) (4)
29/ 12(16) 32/18(23) 25/10(17 )
a 18; v 22(13) 27; 29(18) 12; 12(5) 12; 14(8)
126/27 130/5 193112 173/8
126/44(76) 107/64(82) 141170(103) 108173(82)
69 90 68 102 75
3.2 5.0 3.2 4.6
Severe Trace Trace
195 97 74
0.47 0 .72 0.66
0 23 52 65
0 17 37 50
1.9 1.2
0.95 0 .6
' The subject is male and was born in 1950. Body surface area is 2.0 m", He was in early functional cia" II before aortic valve replacement with a 25 rnrn Carpentier-
Edwards porcine bioprosthe sis in May 1978. Subsequently asymptomatic . he underwent routine cardiac catheterization in May 1979. lie was in functional cia" 111 before
replacement of the stenotic bioprosthetic valve in November 1981 with a Starr-Edwards IDA. model 1260 Silastic ball valve prosthesis.
Figures in parentheses indicate mean values.
Note: Reproduced with the permission of Edward Murphy. MD. Veterans Administration Medical Center. Portland. Oregon.
rate of 10% (37). A combination of symptoms is an ominous
sign (37). In patients with congestive heart failure, the av-
erage life expectancy is less than 2 years (38) .
Aortic re gurgitation with impaired left ventricular
function (13). After successful valve replacement, signif-
icant reductions in left ventricular end-diastolic pressure (16
± 3.2 to 10 ± 2 mm Hg), end-diasto lic volume index (209
Figure 8. Actuarial curve of primary valve failure associated with porcine
heterograft valves. AVR = aortic valve replacement ; MVR = mitral valve
replacement. (Reprinted with permission of Drs. Phillip E. Oyer and Ed-
ward B. Stinson from Stanford University School of Medicine. )
OVERALL VALVE FA ILURE
(Adult Pat ients)
± 15 to 155 ± 17 ml/rrr'), end-systolic volume index (118
± to to 84 ± 14 ml/rrr') and mass (234 ± 11 to 170 ±
16 g/m") occurred (Fig. 11). In general , len ventricular end-
diastolic volume index and mass did not return to normal;
however, the patients with the greatest left ventricular end-
diastolic volumes and mass had major reductions in both
variables .
Left ventricular ejection fraction can be expected to in-
crease in approxi mately half of the patients in this subgroup.
The mean velocity of circumferential fiber shortening in-
creased from 0.72 ± 0.08 to 0.95 ± 0.11 circumferencesls
(p < 0 .05), but became normal in a minority of the patients.
It is likely that left ventricular ejection fraction will improve
in a higher percentage of patients because of better tech-
niques of myocardial protection that have been used more
recent ly.
Incidence Rate at 4 Years'
Table 6. Bjork-Shiley Valve Thrombosis
' By actuarial analysis.
Range includes ± standard error values.
Note: Adapted fromKarp RB,Cyrus RJ, Blackstone EH,etaI. (25) withpermission.
Range
2 to 5%
5 to 27%
7 to 24%
3%
13%
13%
Mean
Aortic
Mitral
Aortic and mitral
72 3 4 5
YEARS POSTOPERATIVE
o
85
w
I-
~ ~
...J z 95
~~
a: a:
~ ~ 90
~
100
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Survival after Valve Replacement
with a Non-cloth-covered, Caged Silos tic Boll Prosthesis
100 100
AORTIC VALVE REPLACEMENT
STARR-EDWARDS MODEL 1260
25
MITRAL VALVE REPLACEMENT
STARR-EDWARDS MODEL 6120
J Mean s rs E.
Figure 9. Fifteen-year survival after aortic and
mitral valve replacement with the Starr-Edwards
Silastic caged-ball prosthesis. which has been un-
changed since 1966. S.E. = standard error.
YEARS
Mitral valve disease. In contrast to aortic valve disease.
patients with mitral valve disease generally do not experi-
ence any significant reduction in left ventricular end-dia-
stolic volume index or ejection fraction (39-42). The cardiac
index tends to improve and usually there are significant
reductions in left atrial pressure (42,43).
Studies utilizing M-mode echocardiography (40) indicate
that ventricular function tends to decrease slightly postop-
eratively in patients with mitral regurgitation, even if it was
within the normal range preoperatively. although when car-
diomegaly is moderate, there is a progressive reduction in
ventricular size and mass. Patients with a marked increase
in left ventricular size preoperatively on M-mode echocar-
diography experienced no change in end-diastolic dimen-
sion, had a Significant increase in end-systolic dimension
and had a significant reduction in the calculated ejection
fraction postoperatively. These data suggest that left ven-
tricular function was depressed to a greater degree than was
apparent from the calculated ejection fraction because of
the low impedance leak from the left ventricle to the left
atrium (44). After the low impedance leak was corrected,
the magnitude of depression of ventricular function became
manifest because the left ventricle now ejected entirely into
the aorta. the serious limitations of M-mode echocardiog-
raphy in evaluating left ventricular function should be kept
in mind.
Other Problems
Coronary Bypass Surgery
The need to perform coronary bypass surgery for associated
coronary artery disease in patients undergoing valvular sur-
Figure 10. Left ventricular ejection fraction (left panel) and mean velocity
of circumferential fiber shortening (Vcf) (right panel) before and after
aortic valve replacement in patients with severe aortic stenosis and heart
failure. Postoperatively. left ventricular ejection fraction was normal in 7
of io patients and mean Vcf was normal in 4 of 6 patients. CHB =
complete heart block; MI = myocardial infarction; Pre-Op = preoperative;
other abbreviations as before. (Reprinted from Smith N. McAnulty JH.
Rahimtoola SH [9], by permission of the American Heart Association.
Inc.)
Ejection Fraction Mean Vct
p<O.OOI 2.0 p<O.OI
1.0
1.8
§Mean 1 SE •0.9 £Mean 1 SE
• 1.60.8
i.4
1
0.7
1.2
0.6 ....
'"-, 1.0
0.5 ..~
0.8
0.4
? 0.6 f0.3
04
0.2
0.2
0.1
Pre-Op Post-Op 0 Pre-011. Post-011.
~ Peri-Op MI and late CHB
• Post-Op:Perivolvulo, Ao,tic Incompetence
VALVULAR HEART DISEASE J AM cou, CARDIOl
1983:199- 215
209
LVEDP LVEDVI LV Moss
P <0.05 P <0.02 300 p<O.O I
0
i..... ! SE
00 f2 2~
f
22 ~
30 ...Ii;
!
<,
~ .. .,~ I~O Ii; I~O
"Ii: <, ..<, ...~ ~
20
t
r 7 ~ 7~10
f ..... •SE~ ..... t SE
0 Pre-op- Post-op- 0 Pre-op- Post-Op" 0 Pre-o~ Post-o~
A P""'OVS 111 1
c Post-OIl CHB
o Post -o " PtflUI,,,lof AI
gery has been questioned (45-47) on the basis of 1) lack
of difficult y in "successfully" undertaking valve replace-
ment in the presence of coronary artery disease , and 2) ab-
sence of differences in surv ival at follow-up of patients with
combined surgery from that of patients who had not under-
gone bypass surgery for associated coronary artery disease .
These comparisons were made in patients in whom the treat-
ment was not assigned on a random basis. the numbers of
patients evaluated were very small and the length of follow-
up was very short .
Effect on survival. Other data (48 .49) show the patient s
who had undergone valve replacement and coronary bypass
surgery for associated coronary artery disease had a 10 year
survival rate similar to that of patients who had undergone
Figu re 11. Left ventricular end-dia stolic pressure (left panel). left ven-
tricular end-diasto lic volume index (center panel ) and left ventricular mass
(right panel ), befo re and after valve replacement in patients with severe
aortic regurgitation and left ventricular dysfunction . Al = aortic incom-
petence; other abbreviations as before . (Reprinted from Clark DG. McAnulty
JH. Rahimtoola SH [13]. by perm ission of the Ameri can Heart Association,
Inc .)
valve replacement alone and who did not have coro nary
bypass surgery (Fig. 12). These studies also were not ran-
domized , and the data do not compare patients who did or
did not undergo bypass surgery for their associated coronary
artery disease. Nevertheless, these data suggest that the
deleterious effect of coron ary artery disease on survival was
overcome by performing coronary bypass surgery and that
the 10 year survival rate of these patients is the same as
-Aortic Valve Replacement and Coronary Bypass-
OBSERVED SURVIVAL
Figure 12. Ten year survival for isolated aortic valve
repl acement in patient s without coron ary disease and for
aortic valve rep laceme nt with coro nary bypa ss surgery
(CBS) in patients with aortic valve disease and assoc iated
coronary artery disease . Survival rates throughout the 10
years are almost identical. Abbreviations as before . (Re-
printed from Starr A. Oregon Health Sciences University,
with permission.)
2! S.E.
0 - '- 0 AVR +CBS (N =197) : mea n age 64
.-e AVR only , 1970 -81(N=595) : mean age 57
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that for patient s treated for isolated valvular heart disease
alone. In addition , coronary bypass surgery can be per-
formed at a low risk, and coronary bypass surgery has al-
read y been demonstrated by prospective randomized studies
to prolon g life in some groups of patient s with coronary
artery disease (for example , those with left main coronary
artery disease and three vessel coronary artery disease [23]).
Difficulties of performing a randomized study. Perhaps
the only way to resolve this issue would be to perform a
prospective randomized study . However, the difficulties of
performing such a study need to be emphasized . The in-
cidence of associated coronary artery disease in patient s with
valvular heart disease who are being considered for valve
surgery ranges from 24 to 35% (one vessel disease in 2 to
18%, two vessel disease in 10 to 13% and three vessel
disease in 7 to 29%). In order to obtain definitive answers
about coronary bypass surgery for isolated coronary artery
disease more than 500 to 1000 randomized patients would
be requi red . When one adds in variables of valvular heart
disease . it is clear that one would require seve ral thousands
of patients with valvular heart disease and associated cor-
onary artery disease to perform a success ful study . It must
be remembered that this subgroup of patients constitutes
only approximately 25 to 35% of the total pool of patients
with valvular heart disease: therefore , an enormous numb er
of patient s will have to be screened in order to obtain several
thousand patients who could be entered into such a pro-
spective randomized study; the difficulties of performing
such a study are evident.
Cardiac Catheterization and Angiography
Recently it has been debated whether patients who are
undergoing valve replacement should (24,50,51) or should
not (46,47) have preoperative cardiac catheterization and
angiography. Major arguments affirming the view that car-
diac catheterization and angio graphy are necessary can be
summarized: I) the logic of the experimental method of
those who recommend cardiac catheterization not be per-
formed- namely, that of studying the need for cardiac cath-
eterization by an evaluation of operative and late mortality
and postoperative complications-is inappropriate: 2) pre-
vious exper ience in bypassing cardiac catheterization does
not prove that it is right and correct to do so: 3) the accur acy
and reproducibility of the history and physical examination
in diagnosing all valve lesions and eva luating their severity
both pre- and postoperatively are not known; 4) the history,
physical examination, chest X-ray film and electrocar-
diogram are not reliable for evaluating left ventricular dys-
function; 5) M-mode echo cardiography is not reliable in
evaluating the severity of all valve disease , evaluating left
ventricular function or detecting malfunction of mechanical
prosthe ses; 6) the history , physical examination and non-
invasive tests are not reliable in detecting the presence,
extent and severity of associated coronary artery disease; 7)
the rel iability of the surgeon in detectin g and accurately
evaluating the seve rity of all valve lesions is not known : 8)
patients with severe valve disease might be den ied surgery:
and 9) patients with mild or moderate valve disease may
undergo unnecessary valve replacement , a potenti ally
disastrou s complication in such patients.
Echocardiography and Radionuclide Studies
Both of these techniques represent major advances in the
diagnosis and evaluation of pat ients with valvular heart dis-
ease (24) . Radionuclide studies provide a reliable quanti-
tation of left ventricular ejection fraction. They also permit
calculation of the total amount of regurgitation present in
the left or right heart valve s if patients have valve regur-
gitation in only one side of the heart (52).
Echocardiography has proved a reliable tool in the di-
agnosis of valvular lesion s; however , in most instances, it
has not proved reliable for assessing the severity of valvular
heart disease. It is extremel y helpful in the diagnose s of
anatomic lesions that were not clinically suspected . M-mode
echocardiography has not been reliable in the quantification ,
and at times in the detection , of left ventricular dysfunction .
Initial data on use of two-dimensional echocardiograph y
(53) are most encouraging and hold great promise that it
may be a much more reliabl e technique than M-mode ech-
ocardiog raphy in evaluating left ventricular function . More-
over, criteria developed from echoca rdiography as indica-
tors for the need for valve surgery have also proved unreliable
(24).
Commissurotomy for Mitral Stenosis
The modern era of surgery for acquired valvular heart dis-
ease began with this procedure . Commissurotomy for mitral
stenosis has undergone many changes, and currently in the
United States this procedure is usually performed under
direct vision with the utilization of extracorporeal circu la-
tion . The results in experienced hands (54) are impressive:
operative mortality rate is low « 1%). perioperative mor-
bidity is small and the 10 year incidence of thromboem-
bolism and death after successful mitral commissurotomy
is 3 ± 2% (Fig. 13). Most pat ients experience an improve-
ment in the symptomatic state and in hemod ynamics with
reduct ion of left atrial and pulmonary artery pressures and
an impro vement in cardiac index (15-17 ,42); however, pa-
tients need reoperation at an increasing rate , approximately
5 to 7 years after successful commissurotomy (54). Mitral
commissurotomy is the procedure of choice in patient s with
isolated seve re mitral stenosis, but it usually is not suitable
for those with a calcified and a rigid nonmobile valve .
Valve Replacement Versus Valve Repair for
Mitral Regurgitation
Mitral valve repair can be successfully performed with ex-
perience in some patients with mitral regurgitation. Late
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Figure 13. Actuarial incidence of survival and free-
dom from thromboembolism and reoperation in \00
patients with severe mitral stenosis after open com-
missurotomy. (Reprinted fromHousman LB. Bonchek
L, Lambert L, et al. [54], with permission.)
survival (Fig. 14), the incidence of thromboembolism , the
symptomatic improvement and the return of hemod ynamics
toward the normal range are most encouraging (55) . The
best results are obtained in patient s with a myxomatous
mitral valve (mitral valve prolapse syndrome); the results
in patients with rheumati c mitral valve disease are discour-
aging and the results in patients with mitral regurgit ation
secondary to coronary artery disease are less than ideal (55).
Vasodilators
By reducing impedance to left ventricular ejection, arterial
dilators favor increased output of blood from the left ven-
tricie to the aorta and , thus, a reduction in mitral regurgi-
tation and left atrial pressure (56, 57) . The same drugs, by
reducing the arterial resistance , favor the forward output of
blood from the aorta to the periphery and , thus, result in a
reduction of aorti c regurgitat ion (58,59). For these reasons,
vasodilators have proved to be of great value in treating
patients with valvular heart disease who have heart failure.
particularly in the presence of acute valvular regurgitation
(56). Long-term treatm ent with arterial dilators in patients
with mitral regurgitation has proved to provide less than
ideal results (57); in 25% of patient s hydralazine had to be
discontinued because of adver se effects, and in another 25
100%
...~'""1'---"'----""",,' -- - -~
90
Figure 14. Actuarially determined survival curve of patients 80
undergoing repair of mitral and mitral plus triscupid valves
for severe mitral or triscupid regurgitation, or both. (Reprinted
from Carpentier A, Chanvaud A, Fabiani IN, et al. [551, with
permission.)
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to 30% the drug produced hemodynamic improvement that
was not translated into symptomatic improvement. Thus, in
a short follow-up period of an average of 13 months, sat-
isfactory results were obtained in less than half of the pa-
tients. In one patient with aortic regurgitation treated with
long-term hydralazine therapy, a major reduction in left
ventricular volume and mass and dramatic improvement in
left ventricular ejection fraction and functional class were
demonstrated (60). The role of arterial dilators in the long-
term treatment of patients with valvular heart disease is
being further evaluated.
Infective Endocarditis
Early diagnosis and treatment of heart failure. The
case fatality rate from infective endocarditis is 30 to 40%
(61,62). Although this is a great improvement over the 95
to 100% mortality rate in the period before antiobiotic ther-
apy, the mortality rate remains remarkably high. The major
cause of death is congestive heart failure. which occurs in
60% of patients. In most instances. heart failure is due to
severe aortic or mitral regurgitation, or both. Valve replace-
ment alleviates the hemodynamic load of valve regurgita-
tion; thus, valve surgery plays an important role in the care
of patients with infective endocarditis. For both native valve
and prosthetic valve endocarditis with heart failure. patients
treated surgically have a lower hospital mortality rate than
those treated nonsurgically (22). These differences are great-
est in patients with moderate and severe heart failure (Table
7). Therefore, if the high mortality rate of congestive heart
failure is to be reduced, early, aggressive diagnosis and
treatment of congestive heart failure are essential. The in-
dications for valve surgery are listed in Table 8.
Treatment regimen. In patients with infective endo-
carditis who have moderate to severe congestive heart fail-
ure, admission to an acute cardiac care unit and hemody-
namic monitoring with a balloon-flotation catheter are
mandatory (62). Appropriate antibiotic therapy should be
started as soon as possible. Medical therapy for heart failure
Table 7. Results of Valve Replacement in Infective
Endocarditis
Congestive
NVE Hospital Deaths PVE Hospital Deaths
Heart Failure Medical Surgical Medical Surgical
Absent-mild l4'7c 6% 250/< 400/<
Moderate 630/< 20%* 1000/< 35%*
Severe 100% 33%* 100% 630/<
Total 440/< 14%* 79C/c 430/<*
*p ~ 0.08 to < 0.001.
NVE and PVE = native and prosthetic valve endocarditis. respectively.
Note. Adapted from Richardson et al. (221. by permission of the American Heart
Association, Inc.
Table 8. Indications for Valve Surgery in Infective Endocarditis
I. Congestive heart failure
2. Infections
a) Uncontrolled by antibiotic therapy
b) Fungal
c) Usually with staphylococcal infections of aortic and mitral
valves
dl Serratia
e) Usually with gram-negative bacillary infection
3. Recurrent septic systemic emboli despite adequate antibiotic therapy
4. Penvalvular and myocardial abscesses
5. Structural damage to valve in association with other catastrophes, for
example. ruptured sinus of Valsalva
6. "Very large" mobile vegetation
should then be promptly instituted with digoxin and diuretic
drugs; vasodilators (arterial or venous dilators, or both) are
also usually needed. Sodium nitroprusside. which is both
an arterial and venous dilator. is the drug of choice in the
acutely ill patient. After the congestive heart failure has
been controlled with aggressive medical therapy, cardiac
catheterization is almost invariably indicated to define the
presence of all correctable lesions. and can be performed
safely at low risk by experienced workers. Valve replace-
ment or repair of any correctable lesions can then be per-
formed on a nonemergent basis once the congestive heart
failure is controlled, regardless of the duration of antibiotic
therapy. When heart failure cannot be controlled, surgery
should not be delayed if the patient has an operable lesion.
The clinical diagnosis and assessment of patients with
infective endocarditis and mild congestive heart failure are
often wrong. Therefore. these patients should also be ad-
mitted to an acute cardiac care unit for hemodynamic mon-
itoring (62). If congestive heart failure is present. medical
therapy consisting of digoxin and diuretic drugs should be
started. Vasodilators are often also needed in these patients.
If the congestive heart failure is not easily controlled with
medical therapy alone, valve replacement should be per-
formed after cardiac catheterization. If the congestive heart
failure is well controlled. medical therapy for the congestive
heart failure and antibiotic drugs for the infection can be
continued and the patients reassessed after 4 to 6 weeks.
It is to be emphasized that the clinical and hemodynamic
spectrum ofpatients with infective endocarditis and conges-
tive heart failure is a continuum; therefore, if one is unsure
whether congestive heart failure is absent. it is mandatory
to find out through hemodynamic monitoring because of the
serious consequences of a clinical error. Clinical assessment
of severity of congestive heart failure and its response to
therapy is often misleading. Only after the severity of
congestive heart failure is hemodynamically assessed can
appropriate decisions be made regarding medical and sur-
gical therapy.
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Acute Valvular Regurgitation
A common cause of acute valvular regurgitat ion is infect ive
endocarditi s. Other causes include dissection of the aorta ,
traum a, myocardial infarct ion and idiopathic causes. Aorti c
regurgit ation associated with dissection of the aorta is an
indication for surgery . Patients who have cardiac traum a
should be fully evaluated and a decision regarding surgery
should be made on the basis of the findings (63). In other
patients, the usual indication for valvular surgery is severe
valvul ar regurgitation associated with symptoms or other
problems such as left ventricular dysfunction.
Etiology of Heart Disease
The onset of better social and hygienic conditions in the
first half of this century resulted in a dramatic reduction in
the incidence of rheumatic fever (64). A reduced incidence
of rheumatic fever would be expected to result in a reduction
in the inciden ce of rheum atic heart disease after several
decades: this expectation has been fulfilled. Currently in the
United States, there is a remarkable reduction in the inci-
dence of rheumatic heart disease and in the percent of pa-
tients who undergo valve surgery becau se of rheumatic in-
volvement of the heart . In large parts of the United States
the most common indication for valve surgery is calcific
aort ic valve stenosis. Prolapse of the mitral valve is a com-
mon valve disease that first gained general clinical recog-
nition in the late 1950s, as is mitral regurgitation resulting
from coro nary artery disease and severe left ventricular dys-
function. Valvular endocarditis is common among intra-
venous drug abusers. Rheumatic heart disease cont inues to
be seen at an increasing rate in those parts of the United
States that have a significant popul ation of immigrants from
underd eveloped parts of the world ; it also continues to be
seen in patients who live in the inner cities .
Antibiotic Prophylaxis
Antibiotic prophylaxis is undert aken in patients with rheu-
matic and other form s of valvular heart disease for two
purposes: I) prevent ion of recurrences of rheumatic fever:
and 2) prevention of infective endocarditis. In patient s who
already have rheumatic heart disease , secondary prevention
is the goal, and several studies have documented the in-
creased risk of further morbidity and mortality from strep-
tococcal infection and the efficacy of antibioti c treatment.
Although the effectiveness of prophylaxis against infective
endocarditi s has not been proved , a lack of effect has also
not been proved . Moreover , infective endo cardit is is as-
socia ted with a high mortality rate , the complications are
often disastrous and, even after success ful treatment. per-
manent and serious sequelae may remain. How often in-
fective endocarditis has been prevented by antibiotic pro-
phylaxis is completely unknown. Therefore , at the present
time , antibiotic proph ylaxis for the prevention of infect ive
endoca rditis is essenti al on clinical grounds and should be
aggressively undertaken. The recommendations of the
American Heart Association for the prevention of recur-
rences of rheumatic fever and for proph ylaxis against in-
fective endocarditis represent the currently recognized stan-
dard of practice in the United States (65- 67).
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